The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer-Reference-Cited by-同舟云学术

The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer

Published:2020-08-27 Issue:10 Volume:8 Page:1251-1261
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Peng Zhi,Cheng Siyuan,Kou Yan,Wang Ziqi,Jin Rong,Hu Han,Zhang Xiaotian,Gong Ji-fang,Li Jian,Lu Ming,Wang Xicheng,Zhou Jun,Lu ZhiHao,Zhang Quan,Tzeng David T.W.,Bi Dongtao,Tan Yan,Shen Lin

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Clinical Medicine Plus X—Young Scholars Project of Peking University

Beijing Municipal Administration of Hospital's Youth Program

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The gut microbiome modulate response to immunotherapy in cancer;Science China Life Sciences;2024-09-02

2. Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity;Cells;2024-08-27

3. Independent risk factor of drug eruption in immune checkpoint inhibitors treated liver cancer patients: high systemic immune-inflammation index;Cutaneous and Ocular Toxicology;2024-08-24

4. Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study;2024-08-21

5. Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer;Medical Oncology;2024-08-20